Research and Development of Fertility Preserving Technology for Women with Gynecological Tumour

Obstetrics and Gynecology Department, Peking University People's Hospital0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•(1) Aged <= 40 years, women with a strong desire for childbearing;
•(2) Women with endometrial atypical hyperplasia and endometrial cancer obtain remission after fertility sparing therapy;
•(3) FIGO (2018 edition) staging: endometrial cancer IAG1-IAG2 Endometrial atypical hyperplasia;
•(4) Imaging examination confirmed that the cancer was localized in the endometrium;
•(5) Both estrogen receptor and progesterone receptor (ER, PR) were positive;
•(6) Peripheral blood CA125 was normal;
•(7) No severe fertility barriers after assessment of fertility ability;
•(8) Women sign informed consent and have better follow-up conditions.

•(1) Women with serious diseases or severe impairment of liver and kidney function;
•(2) Women with endometrioid adenocarcinoma whose pathological stage or grade is higher than that of stage Ia and G2, or those with deep myometrial invasion, cervical invasion, or metastasized to pelvic and abdominal cavity;
•(3) Women with other types of endometrial cancer or other malignant tumors of the reproductive system;
•(4) Chronic diseases which are not suitable for pregnancy.

发起方

Obstetrics and Gynecology Department, Peking University People's Hospital